Skip to: Content
Skip to: Site Navigation
Skip to: Search
MONDAY, NOVEMBER 23, 2009
| Subscribe to Newser's RSS feeds RSS | Follow Newser on Twitter Twitter

NEWS ABOUT: Avastin

Avastin stories: 7 news summaries

Colon Cancer Drug Flunks Important Test

Avastin's effects on early-stage disease don't meet expectations

Apr 22, 09 8:07 AM CDT
(Newser) - Clinical trials to determine the drug Avastin’s effects on early-stage colon cancer were a big disappointment for drug firm Genentech, the New York Times reports. The drug, which is typically used in late-stage cancer, didn’t significantly cut the recurrence rate among 2,700 subjects in the early stages,... More »

MORE ABOUT:
study • drug companies • cancer research • cancer treatment • Genentech • Roche • Avastin • clinical trials

Popular Cancer Drug Is Iffy
and Expensive

Widely prescribed Avastin doesn't prolong life, studies say

Jul 6, 08 10:48 AM CDT
(Newser) - Avastin is one of the most widely prescribed cancer drugs in the world, but it might not work, the New York Times reports. The drug, made by Genentech, brings in about $2.3 billion a year in the US alone, but recent trials have shown that though the drug shrinks... More »

MORE ABOUT:
cancer • breast cancer • lung cancer • prescription drugs • colon cancer • cancer treatment • Avastin • clinical trials

Genes ID Best Patients for Colon Cancer Drug

Step toward 'holy grail' of personalized cancer battle

Jun 2, 08 2:46 AM CDT
(Newser) - Researchers have taken a giant step toward the "holy grail" of personalized cancer treatment—by using genetic profiling to accurately target chemotherapy, Reuters reports. A new genetic test of colon cancer tumors is able to predict with accuracy whether a patient will respond to treatment with the drug Erbitux,... More »

MORE ABOUT:
genetic testing • colon cancer • colorectal cancer • antibodies • genome • Avastin • American Society of Clinical Oncology • ImClone • Erbitux • genotype

Cancer Drug Sales Push Genentech Profits Up 12%

But analysts say Avastin sales slowing

Apr 11, 08 8:28 AM CDT
(Newser) - Biotech firm Genentech said sales of its blockbuster cancer drug Avastin fueled a first-quarter profit increase of 12%, reports the Wall Street Journal, but the $600 million in sales was below analysts’ projected $622 million, causing some to grumble the drug may have reached a sales plateau. Genentech stock... More »

MORE ABOUT:
FDA • breast cancer • corporate earnings • Genentech • Roche Holding • Avastin

FDA Clears Avastin for Breast Cancer

Ruling rejects own panel's advice;
drug now used for lung, colon treatment

Feb 22, 08 6:06 PM CST
(Newser) - The FDA has approved a drug currently prescribed to treat lung and colon cancer for use on breast cancer patients, the AP reports. The decision defies the advice of the FDA's own advisory panel, which recommended that Avastin not be used to treat breast cancer on the grounds that it... More »

MORE ABOUT:
FDA • breast cancer • lung cancer • colon cancer • Genentech • mortality • tumors • Avastin

Street Yawns at Genentech Quarterlies

Despite beating analysts' revenue and profit forecast, biotech's share price drops

Jan 15, 08 11:09 AM CST
(Newser) - Drug maker Genentech – struggling with near-flat sales of its two premier drugs, Avastin and Rituxan – managed to outperform analyst’s fourth quarter expectations – barely, reports the Associated Press. The one-time biotech uber star, which recorded phenomenal growth in each of the two previous years, showed only a... More »

MORE ABOUT:
earnings reports • biotechnology • Genentech • pharmaceutical • Avastin • Rituxan

FDA Panel Rejects Breast Cancer Drug

Uncertainties on risk sink bid to expand
uses for Avastin

Dec 5, 07 4:34 PM CST
(Newser) - An FDA panel rejected a drug to treat advanced breast cancer by 5-to-4 vote, the Wall Street Journal reports. The drug Avastin is already used to treat colon and lung cancer, but the panel said it did not have sufficient data to weigh the risks and benefits of using the... More »

MORE ABOUT:
FDA • breast cancer • Genentech • Avastin

7 Stories


from our news partners

CinemaBlend.com